GLIMPSE study: Impact of Triple Therapy on Lung Function, Health Status and Mortality risk in Patients with Advanced Chronic Obstructive Pulmonary Disease

  • Salva Fatima Heba Department of pharmacy practice, Deccan school of pharmacy, Darussalam, Aghapura, Hyderabad -500001, Telangana, India.
  • Mr Syed Aamir Ali Department of pharmacy practice, Deccan school of pharmacy, Darussalam, Aghapura, Hyderabad -500001, Telangana, India.
  • Dr. Md. Aleemuddin Naveed MBBS, MD , Associate professor, Department of respiratory medicine, Deccan college of medical sciences, DMRL 'X' road, Kanchanbagh, Hyderabad-500058, Telangana, India
  • SalwaMehrin
  • Maaria Gulnaaz
  • Nausheen Fatima

Abstract

Rationale: Benefits of triple therapy have been verified in COPD patients. However there is confined statistics assessing the potential benefits of triple therapy over dual therapy in COPD patients.


Objectives: To estimate the relative impact of triple therapy on lung function, health status and mortality risk compared with ICS/LABA therapy in symptomatic COPD patients with frequent exacerbations in an Indian clinical population.


Method: The GLIMPSE (Lung Function, Health Status and Mortality Risk Assessment in COPD using Triple Therapy) was as a prospective, parallel design, single centre observational study comparing 24 weeks of triple therapy [twice daily combination of Budesonide-Formoterol (100/6 µg) and once daily Tiotropium (9µg)] with ICS/LABA [twice daily Budesonide-Formoterol (100/6µg)]. The primary outcome was mean change in FEV1% predicted and CAT Total score from baseline at week 24. Secondary Outcomes were variation in dyspnea grade and BODE Total score from baseline.


Results: At week 24 in triple therapy (n=70) and ICS/LABA therapy (n=70), mean difference from baseline in FEV1% predicted were 5.40 (95%CI: 1.29 to 9.50) and 1.90 (95%CI: -1.87 to 5.68) respectively, and mean difference in CAT total score from baseline were -5.10 units (95%CI: -3.49 to -6.71) and -1.80 units (95%CI: -0.052 to -3.548) respectively. In addition, there was a statistically significant reduction in dyspnea grading and BODE score with comparable adverse events in both groups.


Conclusion: Overall, the results favoured Triple therapy over dual therapy in advanced symptomatic COPD patients.

Keywords: Chronic Obstructive Pulmonary Disease; Triple Therapy, Lung Function, Health Status, Mortality risk.
Statistics
23 Views | 27 Downloads
How to Cite
Salva Fatima Heba, Mr Syed Aamir Ali, Dr. Md. Aleemuddin Naveed, SalwaMehrin, Maaria Gulnaaz, and Nausheen Fatima. “GLIMPSE Study: Impact of Triple Therapy on Lung Function, Health Status and Mortality Risk in Patients With Advanced Chronic Obstructive Pulmonary Disease ”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 1, Jan. 2021, pp. 190-5, https://innovareacademics.in/journals/index.php/ajpcr/article/view/39505.
Section
Original Article(s)